Skip to main content
NVDA+0.57%AAPL+0.41%GOOGL+0.93%MSFT+0.39%AMZN+0.36%TSM-0.16%SPCX+1.09%META+0.17%AVGO-1.10%TSLA+0.05%SKHY-1.36%MU+0.23%LLY-2.33%BRK-B-0.88%AMD+0.69%JPM-1.24%WMT-2.70%ASMLa-0.27%XOM+0.87%V-1.79%JNJ-1.06%INTC+3.71%0700.HK-0.23%MA-2.15%1398.HK+0.78%ABBV-0.65%CSCO+0.65%LRCX+1.44%CVX-0.08%AMAT-0.12%COST-1.54%AP2d+1.46%ORCL-0.35%BAC-0.96%CAT-1.92%KO-0.88%DELL-0.30%0005.HK-0.63%PG-2.05%HSBA.L-0.64%UNH-2.10%3988.HK+1.16%GE-1.76%1816.HK+0.48%ARM-1.37%0857.HK-0.51%0939.HK+1.34%1288.HK+0.61%PM-1.59%MS-2.43%GBPAUD+1.29%AUDUSD-1.14%GBPCHF+1.04%USDCHF+0.87%GBPCAD+0.84%GBPNZD+0.75%USDTHB+0.71%USDCAD+0.69%EURGBP-0.67%AUDJPY-0.67%GBPJPY+0.65%EURAUD+0.64%NZDUSD-0.61%AUDNZD-0.53%EURUSD-0.52%USDJPY+0.49%AUDCAD-0.48%PLNJPY+0.44%GBPTRY+0.41%NOKJPY+0.34%CHFJPY-0.34%EURCHF+0.34%SGDJPY+0.33%GBPHKD+0.32%AUDCHF-0.30%GBPMXN-0.28%USDTRY+0.28%NZDCHF+0.27%CADJPY-0.19%CADCHF+0.18%GBPZAR+0.18%EURZAR+0.17%EURCAD+0.17%USDCNH-0.17%USDZAR+0.16%USDILS+0.16%USDMXN+0.15%GBPUSD+0.15%EURNZD+0.10%NZDJPY-0.10%EURSGD+0.09%GBPSGD+0.09%EURNOK+0.09%EURSEK+0.09%CHFSGD+0.08%NZDCAD+0.08%CHFNOK+0.08%USDSGD+0.08%CHFSEK+0.07%AUDSGD+0.07%USDSEK+0.07%USDNOK+0.07%NZDMXN+0.06%AUDNOK+0.06%EURCNH+0.04%USDCOP-0.04%USDHKD+0.04%EURJPY-0.03%USDPLN-0.03%AUDDKK-0.03%USDDKK-0.02%EURPLN-0.01%EURCZK-0.01%EURHKD+0.01%NZDSGD0.00%EURDKK0.00%XAGUSD+0.56%GAGUSD+0.56%HG1-0.36%USOIL-0.25%XPTUSD-0.23%S1-0.21%W1+0.15%C1+0.13%COTTON+0.09%XAUUSD+0.08%GAUUSD+0.08%XNGUSD-0.08%BTCUSD-0.16%ETHUSD+7.44%USDTUSD-0.02%XRPUSD+0.63%SOLUSD-0.64%TRXUSDT+0.98%ZECUSDT+0.20%DOGEUSD-0.17%LINKUSD-2.08%XMRUSDT+0.86%XLMUSD+2.50%BCHUSDT-0.35%UNIUSD-0.16%LTCUSD+0.07%SUIUSD+2.15%HBARUSDT+1.57%TONUSD+15.77%TAOUSDT+0.01%AAVEUSD-2.54%DOTUSDT+2.78%ICPUSDT-2.19%ONDOUSDT+0.77%WLDUSDT+10.51%ARBUSDT-0.37%JUPUSDT-0.81%ATOMUSDT+1.10%INJUSDT-3.27%STXUSDT+18.33%FETUSDT+3.24%SEIUSDT+0.33%PYTHUSDT-2.99%TIAUSDT-0.52%IMXUSDT+0.97%GRTUSDT-0.30%OPUSDT-0.24%WIFUSDT+3.04%IOTAUSDT+3.16%POLUSDT-4.48%AXSUSDT+0.67%FARTCOINUSDT-0.15%EOSUSDT+3.86%DYDXUSDT+3.30%GALAUSDT+4.75%ORDIUSDT+1.19%NOTUSDT+1.55%RONINUSDT+0.06%NVDA+0.57%AAPL+0.41%GOOGL+0.93%MSFT+0.39%AMZN+0.36%TSM-0.16%SPCX+1.09%META+0.17%AVGO-1.10%TSLA+0.05%SKHY-1.36%MU+0.23%LLY-2.33%BRK-B-0.88%AMD+0.69%JPM-1.24%WMT-2.70%ASMLa-0.27%XOM+0.87%V-1.79%JNJ-1.06%INTC+3.71%0700.HK-0.23%MA-2.15%1398.HK+0.78%ABBV-0.65%CSCO+0.65%LRCX+1.44%CVX-0.08%AMAT-0.12%COST-1.54%AP2d+1.46%ORCL-0.35%BAC-0.96%CAT-1.92%KO-0.88%DELL-0.30%0005.HK-0.63%PG-2.05%HSBA.L-0.64%UNH-2.10%3988.HK+1.16%GE-1.76%1816.HK+0.48%ARM-1.37%0857.HK-0.51%0939.HK+1.34%1288.HK+0.61%PM-1.59%MS-2.43%GBPAUD+1.29%AUDUSD-1.14%GBPCHF+1.04%USDCHF+0.87%GBPCAD+0.84%GBPNZD+0.75%USDTHB+0.71%USDCAD+0.69%EURGBP-0.67%AUDJPY-0.67%GBPJPY+0.65%EURAUD+0.64%NZDUSD-0.61%AUDNZD-0.53%EURUSD-0.52%USDJPY+0.49%AUDCAD-0.48%PLNJPY+0.44%GBPTRY+0.41%NOKJPY+0.34%CHFJPY-0.34%EURCHF+0.34%SGDJPY+0.33%GBPHKD+0.32%AUDCHF-0.30%GBPMXN-0.28%USDTRY+0.28%NZDCHF+0.27%CADJPY-0.19%CADCHF+0.18%GBPZAR+0.18%EURZAR+0.17%EURCAD+0.17%USDCNH-0.17%USDZAR+0.16%USDILS+0.16%USDMXN+0.15%GBPUSD+0.15%EURNZD+0.10%NZDJPY-0.10%EURSGD+0.09%GBPSGD+0.09%EURNOK+0.09%EURSEK+0.09%CHFSGD+0.08%NZDCAD+0.08%CHFNOK+0.08%USDSGD+0.08%CHFSEK+0.07%AUDSGD+0.07%USDSEK+0.07%USDNOK+0.07%NZDMXN+0.06%AUDNOK+0.06%EURCNH+0.04%USDCOP-0.04%USDHKD+0.04%EURJPY-0.03%USDPLN-0.03%AUDDKK-0.03%USDDKK-0.02%EURPLN-0.01%EURCZK-0.01%EURHKD+0.01%NZDSGD0.00%EURDKK0.00%XAGUSD+0.56%GAGUSD+0.56%HG1-0.36%USOIL-0.25%XPTUSD-0.23%S1-0.21%W1+0.15%C1+0.13%COTTON+0.09%XAUUSD+0.08%GAUUSD+0.08%XNGUSD-0.08%BTCUSD-0.16%ETHUSD+7.44%USDTUSD-0.02%XRPUSD+0.63%SOLUSD-0.64%TRXUSDT+0.98%ZECUSDT+0.20%DOGEUSD-0.17%LINKUSD-2.08%XMRUSDT+0.86%XLMUSD+2.50%BCHUSDT-0.35%UNIUSD-0.16%LTCUSD+0.07%SUIUSD+2.15%HBARUSDT+1.57%TONUSD+15.77%TAOUSDT+0.01%AAVEUSD-2.54%DOTUSDT+2.78%ICPUSDT-2.19%ONDOUSDT+0.77%WLDUSDT+10.51%ARBUSDT-0.37%JUPUSDT-0.81%ATOMUSDT+1.10%INJUSDT-3.27%STXUSDT+18.33%FETUSDT+3.24%SEIUSDT+0.33%PYTHUSDT-2.99%TIAUSDT-0.52%IMXUSDT+0.97%GRTUSDT-0.30%OPUSDT-0.24%WIFUSDT+3.04%IOTAUSDT+3.16%POLUSDT-4.48%AXSUSDT+0.67%FARTCOINUSDT-0.15%EOSUSDT+3.86%DYDXUSDT+3.30%GALAUSDT+4.75%ORDIUSDT+1.19%NOTUSDT+1.55%RONINUSDT+0.06%
AP

Arrowhead Pharmaceuticals, Inc. (ARWR)

NASDAQ • Healthcare

$65.45
-$0.79 (-1.2%)
Market closed

Last close at September 30, 2026 at 20:00 UTC

Open$66.8
Day Range$65.09 - $66.8
Avg. Volume (3M)2.3M
Market Cap$9.2B
52 Week Range
$34.47$95.49
Next EarningsIn 54 daysNov 24, 2026

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned$75.2M100%
Gross Profitminus cost of goods$75.2M100%

Fundamentals & Financials

Revenue (TTM)
$669.4M
Net Income (TTM)
-$319.9M
EPS (TTM)
-$2.24
ROA (TTM)
-15.15%
Current Ratio
5.9
Dividend Yield
0.33%

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

-63.3%Q1 2026$0.22
+14.7%Q2 2026-$0.93
-6.3%Q3 2026-$1.36
Next

Nov 24

in 54 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Miss -6.3%

Arrowhead Pharmaceuticals’ fiscal third quarter of 2026 results, reported August 4, showed a sharp revenue increase year over year, but EPS trailed consensus. Revenue rose 171% to roughly $75.3 million (up from about $27.8 million a year ago), while the company posted a net loss of about $194.3 million, widening by 11% year over year from roughly $175.2 million. On the bottom line, EPS was -$1.36 versus a -$1.28 estimate, trailed by -6.3%, and compared with -$1.26 a year ago (down 8% year over year). Profitability remained negative, with an operating loss of roughly $170.1 million, even as gross profit matched revenue at about $75.3 million. The company also paid roughly $38.4 million in dividends during the quarter. Consensus for the next period calls for EPS of USD -1.52 on revenue of USD 71.8 million.

View full earnings history

About Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) is a biotechnology company that develops RNA interference medicines for complex diseases, with activity centered in the United States. In FY2025, the company recorded $829.4 million in revenue as it advanced a pipeline spanning liver, cardiometabolic, pulmonary, oncology, neuromuscular, inflammatory, and infectious-disease programs.

Name
Arrowhead Pharmaceuticals, Inc.
CEO
Christopher R. Anzalone
Website
arrowheadpharma.com
Industry
Healthcare
Year Founded
1989
Employees
711

Today's Snapshot

AI-generated

The day ended with ARWR 1.2% lower at 65.45, in line with a weaker sector. Shares changed hands at about two-thirds of its usual level.

Trading Volume

Below 10d avg (2.5M)

1.6M

vs S&P 500 Today

Underperforming Market

-1.40%

Updated: September 30, 2026 at 20:11 UTC

Technical Indicators

1 Buy1 Neutral6 Sell
ARWR shows clear bearish characteristics as the stock trades well under most moving averages, including the 200-day, while ADX near the high-20s indicates a persistent downtrend. Momentum measures are weak and MACD is distinctly negative, and the stock’s ATR is elevated, underscoring sizable downside swings. Volume-based OBV is strongly negative, suggesting distribution has accompanied the decline, and short-term oscillators sit near oversold levels but have not confirmed a reversal. Classic pivot sits slightly above the market, providing resistance. Technical takeaway: Strong Sell.
All signals
  • EMA (5 indicators)$68.13 - $77.36
    Sell
  • RSI (14)31.70
    Neutral
  • Stochastic %K (14, 3, 3)7.75
    Buy
  • MACD Level (12, 26)-5.04
    Sell

Peers & Related Assets

KRYSKrystal Biotech, Inc.
$332.56-0.8%
AXSMAxsome Therapeutics, Inc.
$184.39-0.9%
KYMRKymera Therapeutics, Inc.
$111.79+1.2%
TGTXTG Therapeutics, Inc.
$55.78-0.7%
PCVXVaxcyte, Inc.
$56.9+0.4%
ALKSAlkermes plc
$40.52-0.7%
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.